Comparative Pharmacology
Head-to-head clinical analysis: ELELYSO versus VPRIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELELYSO versus VPRIV.
ELELYSO vs VPRIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human glucocerebrosidase; hydrolyzes glucocerebroside to glucose and ceramide, reducing accumulated glucocerebroside in lysosomes of macrophages.
VPRIV (velaglucerase alfa) is a recombinant form of human lysosomal glucocerebrosidase that hydrolyzes glucocerebroside to glucose and ceramide, replacing the deficient enzyme in Gaucher disease.
60 U/kg administered intravenously over 60 minutes every 2 weeks.
60 U/kg intravenously every 2 weeks over 4 hours.
None Documented
None Documented
Mean terminal elimination half-life ranges from 6.1 to 8.9 minutes after intravenous infusion; rapid clearance due to receptor-mediated uptake.
Terminal elimination half-life is approximately 30 minutes (range 15-60 minutes) in Gaucher disease patients, necessitating intravenous infusion over 1-2 hours every other week.
Primarily catabolized via peptide hydrolysis; renal excretion of small peptide fragments and amino acids; less than 1% excreted unchanged in urine.
Primarily metabolized via peptide hydrolysis; elimination is predominantly non-renal. Renal excretion accounts for <5% of the dose as intact drug. Fecal elimination of metabolites is negligible.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy